vip guest (The Center Square) – Homeowners in the market for washers and dryers may have better-performing options to choose from in the near future due to a bill limiting the extent of energy efficiency mandates on laundry appliances passing the U.S. House. The Republican-led House Resolution 1612 , or Liberty in Laundry Act, would prohibit the Secretary of Energy from enforcing energy conservation standards for clothes washers or dryers that “are not cost-effective or technologically feasible.” Rep. Andy Ogles, R-Tenn., who introduced the legislation, said the move is a response to the “slew of woke, ‘environmental’ nonsense rulemaking attempts” by the Biden administration and U.S. Department of Energy. “I have spent much of my time in Congress fighting back the federal government’s vast overreach into the lives of hardworking Americans,” Ogles announced after the bill’s passage Tuesday. “Americans should be able to do their laundry in peace without the input of Big Brother.” Earlier this year, the DOE finalized new updated standards for residential clothes washers and dryers which aim to cut costs and pollution. It estimates the regulations will reduce nearly 71 million metric tons of carbon dioxide emissions–equivalent to the combined annual emissions of nearly 9 million homes–and up to $39 billion on Americans’ energy and water bills over the next 30 years. House Democrats opposed the legislation's passage, saying "absolutely no one" stands to benefit from the law and accused Republicans of trying to curry favor with special interest groups. "H.R. 7673 guts popular energy efficiency standards for laundry machines – standards that save Americans money on their utility bills and reduce dangerous greenhouse gas pollution at the same time," said Energy and Commerce Committee Ranking Member Frank Pallone, Jr., D-N.J. "These efficiency standards create certainty for manufacturers and they protect consumers from rising costs. And, in the case of these laundry machine standards, they also reduce water use – a benefit that could greatly aid drought-prone regions around the nation." But the less electricity and water laundry appliances use, the less effectively they tend to perform, according to an Oct. 2024 report by the Institute for Energy Research. “Historically, appliances meeting Energy Department standards have often underperformed and have higher costs,” the report stated. “The Biden-Harris administration is imposing a series of regulations that are raising appliance prices and compromising quality for homeowners.” Unless the bill is signed into law, laundry appliance makers have until March 2028 to comply with the new rules.

Company experts offer predictions across key sectors to help businesses navigate the unexpected MEMPHIS, Tenn. , Dec. 12, 2024 /PRNewswire/ -- Sedgwick , a leading global provider of claims management, loss adjusting and technology-enabled business solutions, has published its Forecasting 2025 thought leadership report . In preparing the report, Sedgwick's experts conducted research and engaged with clients for notable insights to forecast trends across key sectors and topics. The content focuses on ensuring organizations are aware of new risks and evolving trends and helping them navigate the unexpected in the year ahead. The Forecasting 2025 thought leadership report highlights trends related to: The future of the workplace: Organizational leaders will need to navigate generational differences, an ever-increasing focus on mental health, and new strategies for talent recruitment, retention and development — while developing efficient support systems to respond in the event of workplace injuries, accidents and other crises. Recalls, regulatory landscape and compliance: Strategies like "mock recalls" will be a priority as leaders focus on maintaining public trust, tailoring communication strategies to broader and more segmented audiences, and maximizing awareness and response in the event of a product recall. Catastrophe planning and disaster recovery: Operational continuity in the event of a disaster will be key in 2025, as business and property owners, company leaders and private citizens anticipate the rising frequency and intensity of droughts, extreme temperatures, flooding and storms. Parametric insurance policies will become more common, as will new building methods and construction strategies amid regulatory and policy changes, technological advancements, and environmental, social and governance (ESG) initiatives. AI and ...: Artificial intelligence and robotics have driven some of the most prominent workplace evolutions over the past few years. In 2025, these and other leading-edge technologies will continue to play a significant role in the way companies promote efficiencies and engage with customers. However, business leaders must be able to keep up with new regulations, understand the associated vulnerabilities and risks, and put a team in place to effectively implement and maintain them. Planning ahead: The world is rapidly changing, becoming more uncertain and volatile every day. Supply chain disruptions, new tariffs, more frequent and sophisticated cyber-attacks and business interruption will greatly impact organizations in 2025. Diversification, rapid response and technology will be critical tools in being as prepared as possible. "2024 was a seismic year across industry sectors as companies navigated the unexpected, and 2025 will be no different," said Kimberly George, Sedgwick's Global Chief Brand Officer . "These predictions serve as a barometer for what's to come, so leaders around the world can prepare accordingly." The trends and predictions in the Forecasting 2025 report will be monitored by Sedgwick's experts throughout the year and serve as part of a larger thought leadership strategy to keep clients and partners informed. With this, Sedgwick will launch a new podcast featuring in-depth conversations with its experts and client partners on a new topic each month. For more on the report insights, visit sedgwick.com . About Sedgwick Sedgwick is a leading global provider of claims management, loss adjusting and technology-enabled business solutions. The company provides a broad range of resources tailored to clients' specific needs in casualty, property, marine, benefits, brand protection and other lines. At Sedgwick, caring counts; through the dedication and expertise of over 33,000 colleagues across 80 countries, the company takes care of people and organizations by mitigating and reducing risks and losses, promoting health and productivity, protecting brand reputations, and containing costs that can impact performance. Sedgwick's majority shareholder is The Carlyle Group; Stone Point Capital LLC, Altas Partners, CDPQ, Onex and other management investors are minority shareholders. For more, see sedgwick.com . SOURCE Sedgwick Claims Management Services, Inc.

NEW YORK — Juan Soto put on a New York Mets jersey and cap for the first time Thursday after his record $765 million, 15-year contract was finalized and talked about what made the difference in his decision. “They showed me a lot of love. ... How they're going to make it comfortable for me,” he said. "That's one of the things I was looking for." Soto was introduced at Citi Field a day after his deal was finalized. Speaking in the Piazza 31 Club, he was flanked by Mets owner Steve Cohen, president of baseball operations David Stearns and his agent, Scott Boras. “They always talk about family. They always talk about stick(ing) together,” Soto said. “That's one of the things that opened my eyes.” Security men in gray suits wearing earpieces were off to the side. Soto walked in led by Boras, wearing a dark suit, black turtle neck shirt and gold chain with his No. 22. “I’m excited by the Mets future,” Cohen said. “I think this accelerates our goal of winning championships.” Soto chose the Mets' offer on Sunday, deciding to leave the Yankees after helping them reach the World Series in his only season in the Bronx. SAN FRANCISCO — Willy Adames wasted little time making one thing clear: He wants to play all 162 games for the San Francisco Giants. So when introduced as their new shortstop Thursday, Adames looked to his left and gently put a hand on manager Bob Melvin's right shoulder, smiled and said, “if he lets me.” Melvin might not need much convincing, thrilled to suddenly have stability at a position that lacked continuity this year in his first season as skipper. Adames didn't hesitate to also offer a thought to new boss Buster Posey: He plans to win a few championships with the Giants just like the catcher-turned-executive did here. Surrounded by his parents and other family and friends, Adames was formally introduced and welcomed at Oracle Park after signing a $182 million, seven-year contract — the first big, splashy move made by Posey since he became President of Baseball Operations in late September. “There’s no words to describe my feeling right now to be here in this beautiful city, I’m just so happy to be here,” Adames said. "... This is a dream come true for me. I’m thrilled to be here, I’m so excited. Hopefully we can win a few championships like you did, and that’s one of the main reasons I’m here.” PUERTO PLATA, Dominican Republic — The trial against Tampa Bay Rays shortstop Wander Franco, who has been charged with sexually abusing a minor, sexual and commercial exploitation against a minor, and human trafficking, was postponed on Thursday and scheduled to resume June 2, 2025. Dominican judge Yacaira Veras postponed the hearing at the request of prosecutors because of the absence of several key witnesses in the case. Only three out of 31 witnesses arrived to the hearing on Thursday. Franco’s lawyers asked the court to reconsider the postponement, arguing Franco must report to spring training in mid-February. “There is no case against Wander, for as many witnesses as they present, there is no case now,” Franco's lead lawyer Teodosio Jáquez told The Associated Press after the hearing. The judge replied that Franco is obligated to continue with the trial schedule and his conditional release from detainment. Get local news delivered to your inbox!

Keith Reckdahl breathed a sigh of relief this week after an automatic recount, certified last week, confirmed his narrow 10-vote victory for a seat on the Palo Alto City Council. “There’s a lot of relief — it was a long grind, and the county process was lengthy on top of the recount,” Reckdahl said. Reckdahl, a planning and transportation commissioner, initially led fellow commissioner Doria Summa by just 12 votes, 11,539 to 11,527. However, last month’s recount tightened the race even further, leaving Reckdahl with a razor-thin 10-vote lead, 11,561 to 11,551, according to the official count from Santa Clara County Registrar of Voters. The Palo Alto race was , including contests in Fremont, Cupertino, and Newark. In Newark, Julie Del Cantancio . Incumbents Greer Stone, the current mayor, and Pat Burt, along with newcomer George Lu, secured their seats on the council early in the race. With two new members joining the council, Reckdahl emphasized the importance of fresh perspectives. “The council has a few new people, and that’s good,” Reckdahl said. “It’s always valuable to have a variety of voices. You don’t want groupthink, where everyone’s thinking exactly the same.” One of Reckdahl’s top priorities when he takes office in January is to increase the housing supply and “modernize” downtown zoning. “The council is committed to adding more housing, but there are still many details to address,” Reckdahl said. “We must continue pushing aggressively to create more housing in the city. As for retail, we have some vacancies, and we’re working on modernizing downtown zoning to make the area more attractive. These efforts are already underway, but there’s still much to be done.” Palo Alto’s housing plan, officially known as the housing element, was certified in August after being sent back by the California Department of Housing and Community Development. In April, the city revised its plans to include measures for increasing access for minorities and zoning for multi-family construction. To meet its state-mandated housing targets, . “The housing element took a lot of time, which diverted attention from other city matters,” Reckdahl said. California Avenue, one of Palo Alto’s two downtown areas that features parklets, mom-and-pop shops, cafes, and restaurants, as many tech companies and start-ups shifted to remote work. The council has been discussing ways to revitalize the area, but so far, efforts such as new signage, painted planters, bike lanes, and bollards have not been enough to boost foot traffic. “If you go down to California Avenue, it just looks like a cold street,” Reckdahl said. “It doesn’t look like an attractive shopping area, but it has so much potential.” In addition to serving on Palo Alto’s Planning and Transportation Commission, Reckdahl has worked as an aerospace engineer for Lockheed Martin since 2005 and is a graduate of Stanford University.

NEW YORK , Dec. 9, 2024 /PRNewswire/ -- Report with the AI impact on market trends - The global publishing market size is estimated to grow by USD 19.37 billion from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of 1.2% during the forecast period. Increase in demand for diversity in content is driving market growth, with a trend towards rise in number of self-published authors. However, decreasing market share of traditional publishing poses a challenge. Key market players include Adobe Inc., Amazon.com Inc., Bertelsmann SE and Co. KGaA, Bloomsbury Publishing Plc, Cambridge University Press, Georg von Holtzbrinck GmbH and Co. KG, Haufe Lexware GmbH and Co. KG, John Wiley and Sons Inc., McGraw Hill LLC, MPS Ltd., News Corp., Oxford University Press, Pearson Plc, PLANETA CORPORACION Srl, Scholastic Corp., Thomson Reuters Corp., Vivendi SE, White Falcon Publishing Solutions LLP, Wolters Kluwer NV, YUDU Ltd., Lerner Publishing Group, and Blue Heron Book Works. AI-Powered Market Evolution Insights. Our comprehensive market report ready with the latest trends, growth opportunities, and strategic analysis- View Free Sample Report PDF Key Market Trends Fueling Growth The self-publishing trend has significantly increased the number of books in the global publishing market. Aspiring authors now have the opportunity to publish their work independently, retaining full control and earning higher royalties, typically around 60%-80% of the book's listed price. Self-publishing saves time, cost, and eliminates the risk of losing rights to traditional publishers. Digital platforms like Amazon KDP and Smashwords expand reach with minimal upfront costs, leading to an increase in indie and self-published authors and titles, fueling market growth. The publishing market is currently experiencing significant growth in various areas. One trending sector is eBooks, which have become increasingly popular due to their convenience and accessibility. Another trend is the use of chatbots for marketing and customer service in the publishing industry. Additionally, social media is playing a major role in promoting books and reaching new audiences. The use of analytics and data-driven insights is also becoming essential for publishers to make informed decisions. Furthermore, the rise of self-publishing and print-on-demand technology is giving authors more control over their work and reducing inventory costs. Overall, the publishing industry is adapting to new technologies and consumer preferences to stay competitive. Insights on how AI is driving innovation, efficiency, and market growth- Request Sample! • The publishing market faces challenges from shifting consumer preferences towards digital formats. Declining demand for traditional print publications, due to convenience and environmental concerns, puts pressure on profit margins with significant production and distribution costs. Major US newspapers, like The New York Times and The Wall Street Journal, have seen growth in digital subscriptions, but overall print demand continues to decline. Self-publishing platforms add competition, impacting market share and revenue for traditional publishers in both newspaper and book sectors. • In the publishing market, challenges abound for both traditional and digital players. Classics and new releases, sales and marketing, distribution and logistics, and digital transformation are key areas of concern. Diversifying revenue streams through subscriptions, e-books, and audiobooks is essential for staying competitive. The digital shift requires rich content, user-friendly platforms, and security. Localization and globalization add complexity, while regulatory compliance and data privacy are critical concerns. Collaboration and partnerships are vital for success in this dynamic industry. Insights into how AI is reshaping industries and driving growth- Download a Sample Report This publishing market report extensively covers market segmentation by 1.1 Book publishing 1.2 Magazine publishing 1.3 Newspaper publishing 2.1 Traditional 2.2 Digital 3.1 North America 3.2 Europe 3.3 APAC 3.4 Middle East and Africa 3.5 South America 1.1 Book publishing- The educational sector's demand for books continues to grow, driven by increasing student populations and expanding access to education. Publishers respond with digital solutions and diverse content. Governments in developing countries, such as India under Sarva Shiksha Abhiyan, prioritize free education. The rise of eBooks and audiobooks broadens the market, enabling instant access and increased consumption. Independent publishing adds unique voices and niche topics, fueling market growth. Education expansion remains a key driver for the book publishing segment. Download complimentary Sample Report to gain insights into AI's impact on market dynamics, emerging trends, and future opportunities- including forecast (2024-2028) and historic data (2018 - 2022) The publishing market encompasses a vast array of genres and formats, catering to the diverse reading preferences of individuals. Notable categories include Mystery, with its intriguing plots and puzzles reminiscent of jigsaws and Rubik's cubes; Educational books, which delve into the realms of Science, as explored by luminaries like Charles Darwin , Albert Einstein , Carl Sagan , and Richard Dawkins ; and Fiction, with its captivating narratives in Romance, Women's Fiction, Young Adult, and Classics. The marketplace is populated by local bookshops, such as Kitabay, and online portals, providing access to a multitude of prospects for both physical stores and online businesses. Stock market and housing market books offer insights into potential buyers' interests, while costs vary between formats and genres. Reading enthusiasts seek out these resources, expanding their knowledge and imagination. The Publishing Market encompasses a wide range of industries and sectors, including print and digital media, educational publishing, scientific, technical and medical (STM) publishing, and academic publishing. This market is driven by various factors such as increasing literacy rates, growing demand for knowledge and information, and the shift towards digital content. The market is also influenced by trends like self-publishing, open access publishing, and subscription models. Publishers are leveraging technologies like artificial intelligence and machine learning to enhance content discovery and personalization. The market is expected to grow significantly in the coming years due to these factors and the increasing adoption of digital content. 1 Executive Summary 2 Market Landscape 3 Market Sizing 4 Historic Market Size 5 Five Forces Analysis 6 Market Segmentation Type Book Publishing Magazine Publishing Newspaper Publishing Platform Traditional Digital Geography North America Europe APAC Middle East And Africa South America 7 Customer Landscape 8 Geographic Landscape 9 Drivers, Challenges, and Trends 10 Company Landscape 11 Company Analysis 12 Appendix Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios. Technavio Research Jesse Maida Media & Marketing Executive US: +1 844 364 1100 UK: +44 203 893 3200 Email: [email protected] Website: www.technavio.com/ SOURCE TechnavioHERZLIYA, Israel and CALGARY, Alberta , Dec. 12, 2024 /PRNewswire/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF ) (the "Company" or "Innocan") a pharmaceutical technology company focusing on developing innovative drug delivery platform technologies and an owner of a proprietary intellectual property portfolio, is pleased to share its annual "State of Research and Development" update for 2024. This year, the Company achieved significant milestones in advancing research and development for its drug delivery platforms as well as its intellectual property portfolio. During 2024, Innocan achieved significant milestones in both scientific and regulatory domains. Preclinical studies of its liposome-cannabidiol technology (LPT - CBD ( demonstrated high CBD bioavailability, along with long-lasting pain relief and improved well-being in various animal models. Building on this compelling data, the Company secured agreement from the United States Food and Drug Administration (FDA) on the preclinical and Phase 1 clinical development plan to advance LPT-CBD as a treatment for chronic pain in humans. Additionally, the FDA acknowledged LPT-CBD's development under the 505(b)(2) regulatory pathway, which provides Innocan with an accelerated route to patent utilization and commercialization. On the veterinary front, LPT-CBD's innovation was recognized by the FDA's Center for Veterinary Medicine (CVM), which granted Innocan a fee waiver for 2024 and issued a number that identifies an Investigational New Animal Drug (INAD). This designation allows Innocan to facilitate correspondence and data exchange with the CVM to support the development of LPT-CBD as a new veterinary drug. Iris Bincovich, CEO of Innocan Pharma, commented: "In 2024, we not only met but surpassed our FDA-related goals, achieving regulatory milestones ahead of schedule. With the FDA 505(b)(2) regulatory pathway meeting behind us, these advancements position us to accelerate our development in 2025, bringing us closer to delivering innovative pain management solutions for both human and veterinary applications." The 505(b)(2) FDA regulatory pathway offers a streamlined approach for developing a long-acting injectable cannabinoid using a liposomal drug delivery platform to treat chronic pain. By leveraging existing pre-clinical data from approved products, this pathway is expected to significantly shorten both development time and cost. This pathway facilitates innovative formulations like liposomal delivery, by allowing for modifications to dosage forms, administration routes, or drug combinations, all while adhering to stringent safety and efficacy standards. This approach is expected to accelerate market entry and address unmet medical needs in chronic pain management. Company ' s Update on its Activity in Research and Development and FDA interactions On February 26, 2024 , the Company announced the latest findings from the Company's pharmacokinetic study of its liposome CBD platform ("LPT-CBD") in rabbits. In agreement with studies conducted in other animals (mice, dogs, goats, and sheep) this study resulted in prolonged exposure of CBD obtained following a single subcutaneous LPT-CBD injection. This data along with data obtained from other organisms injected with the Company's liposomal CBD, consistently demonstrates that a detectable CBD level could be maintained for weeks following a single injection. On March 5, 2024 , the Company announced the results of a recent tissue distribution study of its liposome CBD platform (LPT-CBD), that indicated the potential of LPT-CBD to support a new therapeutic venue for neurological disorders. In this study, CBD was found to be in the brains of both mice and rabbits weeks after LPT-CBD was subcutaneously injected to them. LPT technology provides a long presence of CBD in the blood enabling CBD to pass the blood brain barrier (BBB) and deliver long brain exposure. On April 22, 2024 , the Company announced that it had submitted its letter of application for a Pre-IND meeting, the first phase in the FDA approval process in the United States for LPT-CBD. Innocan's Pre-IND meeting request letter to the FDA represents a key milestone and important first step in seeking approval of its LPT-CBD therapy for use in humans. The objective of the Pre-IND meeting is to obtain guidance from the FDA on the preclinical and clinical development plan, enabling the initiation of an investigational new drug ("IND") program in the United States . On May 9, 2024 , the Company announced the successful pre-clinical treatment of amputee female donkey with a liposomal-CBD injection. Miri, a-7-year-old female donkey, had undergone amputation of her right front limb, leaving the weight burden primarily on her left front limb. This led to an inflammatory disease affecting the soft tissue that connects the foot bone to the hoof, seemingly causing extreme pain and limited mobility. In a compassionate act, Miri was administered a liposomal-CBD injection. The effect was immediate as Miri regained her ability to walk and move as she had before her inflammatory disease developed. On May 21, 2024 , the Company announced significant advancements in the regulatory process for its LPT - CBD, which provides an innovative solution in non-opioid pain management. The FDA granted Innocan an INAD number and approved an initial meeting with the Company to discuss the strategic path forward. The meeting with the FDA was on July 31, 2024 , where Innocan presented its preclinical results and proposed clinical development plan. The meeting is key to launching human clinical trials for the LPT-CBD injectable drug, developed to provide a novel treatment option for chronic pain. On June 11, 2024 , the Company announced the success and conclusion of a preliminary safety evaluation of Innocan's single injection and sustained-release LPT-CBD conducted on minipigs. Recognized by the FDA as an excellent model for toxicology, minipigs are small breeds of miniature domestic pigs which share strong similarities with humans in crucial aspects such as drug metabolism, skin structure, genetics, and physiological mechanisms. In this preliminary safety study, minipigs received a single subcutaneous injection of LPT-CBD and were closely monitored for pharmacokinetics and basic safety parameters over one month. The animals all exhibited good drug tolerance and did not manifest any drug-related adverse reactions. On July 2, 2024 , the Company announced that it engaged the Past President of the Eastern Pain Association, Dr. William K. Schmidt , to support its LPT-CBD submission process to the FDA for chronic pain. His extensive expertise in pain-related clinical development and regulatory affairs will strongly contribute to Innocan's team during the LPT-CBD submission process with the FDA. Dr. Schmidt brings over 25 years of pharmaceutical industry clinical trial experience, specializing in analgesic and narcotic antagonist drug development. On July 26, 2024 , the Company announced that the CVM) granted the Company a sponsor fee waiver and assigned an INAD number for its LPT-CBD product. This represented a significant step for the Company, as an INAD designation facilitates correspondence and data exchange with CVM to support LPT-CBD development as a new veterinary drug. The Company further announced that following the assessment of LPT-CBD's scientific package, the CVM recognized Innocan's contribution to pursuing innovative animal drug products and technology and granted the Company a sponsor fee waiver for fiscal year 2024. Over the past year, repeated administration of LPT-CBD in dogs and other animals demonstrated both efficacy and tolerability, providing sufficient evidence for the INAD application. On September 3, 2024 , the Company announced that it received a positive response from the FDA following Innocan's successful pre-IND Type B meeting with the FDA held in July, for its lead drug product LPT-CBD. The FDA has agreed to LPT-CBD's submission under the 505(b)(2) New Drug Application (NDA) by establishing a scientific bridge to the reference listed drug. The 505(b)(2) abbreviated pathway, as it is often described, typically enables a faster route to patent utilization and commercial approval. This pathway is a significant milestone for Innocan, as it may pave the way for a streamlined and accelerated FDA approval process for LPT-CBD, while allowing Innocan to advance its patent protected innovation. In addition, Innocan has reached an alignment with the FDA on both its non-clinical development plan and the clinical study design for LPT-CBD's proposed IND filing for a Phase I clinical study. On October 9, 2024 , The Company announced that Dr. Joseph V. Pergolizzi, Jr. , M.D., a member of the Company's Scientific Advisory Board, was recognized among the top 2% most cited scientists in the world in a new list published by Stanford University . This achievement underscores Dr. Pergolizzi's long-term contribution to medical science and his influential role in shaping global healthcare practices. Dr. Pergolizzi was appointed to be part of Innocan's Scientific Advisory Board in September 2023 . His role focuses on promoting pharmaceutical human product R&D and supporting the Company's planned FDA filing for new medications. His expertise in pain management, critical care medicine, and regulatory processes are key in advancing the issuer's pharmaceutical developments. On October 11, 2024 , the Company announced promising results from a multi-year compassionate therapy using repeated LPT-CBD injections for pain relief in dogs with naturally occurring osteoarthritis. The therapy consistently demonstrated pain reduction and improved mobility, with effects lasting for several weeks after each injection as expected. These results further demonstrate that LPT-CBD can be a viable treatment option for managing chronic pain and enhancing the quality of life in animals. In two ongoing cases, dogs suffering from osteoarthritis who were treated with LPT-CBD after failing to respond to non-steroidal anti-inflammatory drugs (NSAIDs) and oral CBD, showed noticeable pain relief, substantially improved mobility and increased well-being which was clearly noticeable. Both dogs remained on LPT-CBD treatment for 2 and 2.5 years, respectively after their owners reported significant improvement in quality of life, receiving the treatment in addition to other conventional treatments. About Innocan Innocan is an innovator in the pharmaceuticals and wellness sectors. In the pharmaceuticals sector, Innocan developed a CBD-loaded liposome drug delivery platform with exact dosing, prolonged and controlled release of synthetic CBD for non-opioid pain management. In the wellness sector, Innocan develops and markets a wide portfolio of high-performance self-care and beauty products to promote a healthier lifestyle. Under this segment Innocan carries on business through its 60% owned subsidiary, BI Sky Global Ltd. which focuses on advanced, targeted online sales. www.innocanpharma.com For further information, please contact: Iris Bincovich, CEO +1-516-210-4025 +972-54-3012842 +44 203 769 9377 [email protected] NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE. Cautionary note regarding forward-looking information Certain information set forth in this news release, including, without limitation, information regarding research and development, collaborations, the filing of potential applications with the FDA and other regulatory authorities, the potential achievement of future regulatory milestones, the potential for treatment of conditions and other therapeutic effects resulting from research activities and/or the Company's products, requisite regulatory approvals and the timing for market entry and potential for patent utilization and commercialization is forward-looking information within the meaning of applicable securities laws. By its nature, forward-looking information is subject to numerous risks and uncertainties, some of which are beyond Innocan's control. The forward-looking information contained in this news release is based on certain key expectations and assumptions made by Innocan, including expectations and assumptions concerning the anticipated benefits of the products, satisfaction of regulatory requirements in various jurisdictions and satisfactory completion of requisite production and distribution arrangements. Forward-looking information is subject to various risks and uncertainties which could cause actual results and experience to differ materially from the anticipated results or expectations expressed in this news release. The key risks and uncertainties include but are not limited to: general global and local (national) economic, market and business conditions; governmental and regulatory requirements and actions by governmental authorities; and relationships with suppliers, manufacturers, customers, business partners and competitors. There are also risks that are inherent in the nature of product distribution, including import / export matters and the failure to obtain any required regulatory and other approvals (or to do so in a timely manner) and availability in each market of product inputs and finished products. The anticipated timeline for entry to markets may change for a number of reasons, including the inability to secure necessary regulatory requirements, or the need for additional time to conclude and/or satisfy the manufacturing and distribution arrangements. As a result of the foregoing, readers should not place undue reliance on the forward-looking information contained in this news release concerning the timing of launch of product distribution. A comprehensive discussion of other risks that impact Innocan can also be found in Innocan's public reports and filings which are available under Innocan's profile at www.sedar.com . Readers are cautioned that undue reliance should not be placed on forward-looking information as actual results may vary materially from the forward-looking information. Innocan does not undertake to update, correct or revise any forward looking information as a result of any new information, future events or otherwise, except as may be required by applicable law. Logo - https://mma.prnewswire.com/media/2570689/Innocan_Pharma_Logo.jpg SOURCE Innocan Pharma Corporation